IGF1R: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of IGF1R. The page also collects GeneMedi's different modalities and formats products for IGF1R in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the IGF1R target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
This receptor binds insulin-like growth factor with a high affinity. It has tyrosine kinase activity. The insulin-like growth factor I receptor plays a critical role in transformation events. Cleavage of the precursor generates alpha and beta subunits. It is highly overexpressed in most malignant tissues where it functions as an anti-apoptotic agent by enhancing cell survival. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, May 2014]
|Gene Official Name||IGF1R|
|Gene Alias||CD221, IGFIR, IGFR, JTK13|
|Protein Sub-location||Transmembrane Protein|
|Category||Therapeutics Target, INN Index, Cytokine Target, Immuno-oncology Target|
Pre-made IGF1R-specific INN-index biosimilar (antibody&conjugates)-Ganitumab, Figitumumab, Istiratumab, Lonigutamab, Robatumumab, Teprotumumab, lonigutamab ugodotin, Cixutumumab, Dalotuzumab
Anti-IGF1R therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Pre-made anti-IGF1R inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-IGF1R benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-IGF1R mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Cat No.||Antibody Name||Format||Classified by tag||Order|
|GM-Tg-hg-T48069-Ab||Anti-IGF1R monoclonal antibody||mab||Biofunctional antibody, Therapeutics Target antibody, Cytokine antibody|